Peter Loftus

Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced injectables.

Sign of the times: telehealth firm's ad for weight-loss drugs to run during Super Bowl (by my colleague Katie Deighton): www.wsj.com/articles/him...

Ozempic Among the Next Drugs Up for Medicare Price Negotiations List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

Breaking: Ozempic and Wegovy are among 15 drugs up for a new round of price negotiations by Medicare

JPMorgan Hosts First Major Healthcare Gathering Since Death of UnitedHealthcare’s CEO Industry leaders from more than 500 companies scheduled to give investor presentations will see heightened security surrounding the conference and related events. Many will have personal bodyguards.

JPMorgan is hosting its first major healthcare gathering since the death of UnitedHealthcare’s CEO Brian Thompson and security around industry leaders will be heavy

Got news tips for The Wall Street Journal? Here are some secure ways to send tips or documents, anonymously or otherwise: www.wsj.com/tips

Amgen Obesity Drug Cut Weight In Closely Watched Study Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

In other obesity drug news, Amgen shares are down more than 10% today because investors were underwhelmed by magnitude of weight loss, tolerability data from new study of its experimental med: www.wsj.com/health/pharm...

White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.

Will Medicare and Medicaid broadly cover anti-obesity meds like Wegovy? Outgoing Biden administration proposes it, up to incoming Trump admin to keep or scrap it. W/ @lizessleywhyte.bsky.social : www.wsj.com/health/healt...

Makers of Weight-Loss Drugs Want Your Employer to Pay for Them Eli Lilly, Novo Nordisk reps get facetime with employers in hopes they’ll cover their drugs

The tried-and-true pharma marketing methods--TV ads, sales reps, etc.--only go so far when it comes to weight loss drugs. That's why Lilly and Novo are sending reps to employers, to get more of them to cover the drugs. It's not an easy sell, because of the high cost: www.wsj.com/health/pharm...

I wrote about the increasing use of an unusual treatment for difficult depression, J&J's Spravato, a cousin of ketamine: www.wsj.com/health/healt...

Novo Nordisk's planned purchase of Catalent's manufacturing plants underscores the mismatch between demand and supply of popular new weight loss drugs: www.wsj.com/business/dea...